Skip to main content


Swipe om te navigeren naar een ander artikel

01-04-2010 | Original article | Uitgave 4/2010

Netherlands Heart Journal 4/2010

Neurohormonal profile of patients with heart failure and diabetes

Netherlands Heart Journal > Uitgave 4/2010
I. C. C. van der Horst, R. A. de Boer, H. L. Hillege, F. Boomsma, A. A. Voors, D. J. van Veldhuisen
Belangrijke opmerkingen
Department of Cardiology, University Medical Center Groningen, University of Groningen, the Netherlands
Departments of Cardiology, and Epidemiology, University Medical Center Groningen, University of Groningen, the Netherlands
Department of Internal Medicine, Section of Vascular Pharmacology, Erasmus MC, Rotterdam, the Netherlands


Background. Neurohormonal activation is generally recognised to play an important role in the pathophysiology, prognosis and treatment of chronic heart failure (HF). While the number of patients with diabetes increases, little if anything is known about neurohormonal activation in HF patients with diabetes.
Methods. The study population consisted of 371 patients with advanced HF who were enrolled in a multicentre survival trial. Ten different plasma neurohormones were measured (noradrenaline, adrenaline, dopamine, aldosterone, renin, endothelin, atrial natriuretic peptide [ANP], N-terminal (pro)ANP, brain natriuretic peptide [BNP] and N-terminal (pro)BNP. Comparisons were made between patients with diabetes (n=81) and those without (n=290).
Results. At baseline, the two groups were comparable regarding age (mean 68 years), left ventricular ejection fraction (23%), severity and aetiology of HF, while body weight was higher in those with diabetes (77.4 vs. 74.2 kg, p=0.04). Most plasma neurohormones were similar between groups, but patients with diabetes had higher values of BNP (94 vs. 47 pmol/l, p=0.03), while a similar trend was observed for N-terminal (pro)BNP (750 vs. 554 pmol/l, p=0.10). During almost five years of follow-up, 51/81 patients with diabetes died (63%), as compared with 144 of 290 non-diabetic patients (50%) who died (p=0.046). Natriuretic peptides and noradrenaline were the most powerful predictors of mortality in both diabetic and non-diabetic HF patients.
Conclusion. HF patients with diabetes have higher (N-terminal (pro)) BNP levels than non-diabetic patients, while other neurohormones are generally similar. Natriuretic peptides are also good prognostic markers in diabetic HF patients. (Neth Heart J 2010;18:190-6.)

Log in om toegang te krijgen

Met onderstaand(e) abonnement(en) heeft u direct toegang:

Netherlands Heart Journal

Het Netherlands Heart Journal wordt uitgegeven in samenwerking met de Nederlandse Vereniging voor Cardiologie en de Nederlandse Hartstichting. Het tijdschrift is Engelstalig en wordt gratis beschikbaa ...

Over dit artikel

Andere artikelen Uitgave 4/2010

Netherlands Heart Journal 4/2010 Naar de uitgave